Literature DB >> 1849792

Altered HLA class I expression in non-small cell lung cancer is independent of c-myc activation.

M Redondo1, F Ruiz-Cabello, A Concha, T Cabrera, M Pérez-Ayala, M R Oliva, F Garrido.   

Abstract

We studied the expression of major histocompatibility complex class I antigens in 59 bronchogenic carcinomas, as well as in pneumocytes and epithelial respiratory cells distant from the tumor. We observed in all cases that normal lung tissue expressed major histocompatibility complex class I antigens, while this expression was completely lost in 16 tumors (27%). The defect in HLA gene expression affected both heavy chain and beta 2-microglobulin, as demonstrated by the null reactivity with the monoclonal antibodies GRH1, W6/32, and HC10. Selective underexpression was detected in 1 tumor for HLA-A locus antigens and in 3 tumors for HLA-B locus antigens. Southern blot analyses of major histocompatibility complex class I genes were performed in 20 tumor tissue specimens and 6 cell lines. No class I gene rearrangements were detected using HLA coding and locus specific noncoding probes. We also used the Southern blot method to investigate the possible relationship between c-myc amplification and HLA class I antigens in non-small cell lung cancers and detected no apparent amplification in 20 tumor tissue specimens (5 negative for HLA class I antigens) and 6 cell lines (3 with decreased expression). Northern blot analysis revealed no relationship between c-myc mRNA levels and specific mRNA for HLA-A and HLA-B antigens in cell lines with imbalanced HLA-A or HLA-B expression.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1849792

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression.

Authors:  Barry A Kriegsman; Pranitha Vangala; Benjamin J Chen; Paul Meraner; Abraham L Brass; Manuel Garber; Kenneth L Rock
Journal:  J Immunol       Date:  2019-08-30       Impact factor: 5.422

Review 2.  Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.

Authors:  Karthik Dhatchinamoorthy; Jeff D Colbert; Kenneth L Rock
Journal:  Front Immunol       Date:  2021-03-09       Impact factor: 7.561

3.  Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer.

Authors:  P Korkolopoulou; L Kaklamanis; F Pezzella; A L Harris; K C Gatter
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

4.  Clinical relevance and functional implications for human leucocyte antigen-g expression in non-small-cell lung cancer.

Authors:  A Lin; C-C Zhu; H-X Chen; B-F Chen; X Zhang; J-G Zhang; Q Wang; W-J Zhou; W Hu; H-H Yang; H-H Xu; W-H Yan
Journal:  J Cell Mol Med       Date:  2010-09       Impact factor: 5.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.